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Treatment of systemic sclerosis with tocilizumab
SIR, SSc has a highly variable clinical picture and different
levels of severity. Despite innumerable attempts to identify
potential drugs, there is a lack of effective immunomodu-
latory therapies [1, 2]. IL-6 overexpression and pathogen-
icity in SSc have been demonstrated [3], and the effects of
IL-6 in the SSc fibrotic response in vitro are concentration
dependent [4], thus providing the rationale for its
antagonization with tocilizumab (TCZ) [5]. Two cases of
SSc treated with TCZ have been published [6]. In addition,
TCZ has been demonstrated to be effective in SSc-poly-
arthritis in a trial that enrolled 15 patients treated with TCZ
[7]. We report a mini-series of three patients with refrac-
tory SSc (patients 1, 2 and 3), treated with TCZ (8 mg/kg
every 4 weeks). They were all female, and age at the time
of SSc diagnosis was 52 (patient 1), 34 (patient 2) and 53
(patient 3) years old. The time lapse since diagnosis was 3
years, 8 years and 1 year, respectively. At baseline, the
manifestations were as follows: skin thickening in face,
hands (patients 1, 2 and 3), forearms, trunk (patients 1
and 2) and lower legs (patient 2); facial telangiectasias
(patients 13); RP (patients 1, 2 and 3); digital ulcers in
PIP joints (patient 1 with three ulcers and patient 2 with
eight ulcers); arthralgias of PIP joints, wrists, elbows
(patients 1 and 2), shoulders (patients 2 and 3) and MCP
joints (patient 3), with synovitis only in PIPs and MCPs of
patient 3; gastro-oesophageal reflux (patients 1 and 2),
malabsorption syndrome (patient 1); intestinal infarction
(patient 2); non-specific interstitial pneumonia, according
to the scoring system proposed by Wells [8] (patient 1 with
TABLE 1 Evaluated parameters at baseline and after the first tocilizumab infusion
Parameter Patient Baseline 6 months 9 months
mRSS 1 17 11 
2 41 25 
3 7 5 
Digital ulcers, n 1 3 0 
2 8 0 
3 0 0 
Weight, kg 1 35 47 
2 49 57 
3 70 62 
Patient global assessment (0100) 1 70 40 
2 70 30 
3 60 10 
Haemoglobin, g/dl 1 9.5 11.5 
2 11.8 13.3 
3 14.2 14.7 
ESR, mm/h 1 86 55 
2 46 5 
3 3 3 
CRP, mg/dl 1 8.1 1.9 
2 1.75 0 
3 0 0 
DLCO, % 1 47.8 50 
2 72.1 75 
3 78 63 
Chest CT (Wells’ score) 1 Global disease extent 40%  No change
Reticular 40%
Ground glass 60%
2 Global disease extent 15%  No change
Reticular 20%
Ground glass 80%
3 Global disease extent 20%  Global disease extent 25%
Reticular 10% Reticular 15%
Ground glass 60% Ground glass 85%
mRSS: modified Rodnan Skin Score; DLCO: diffusing capacity for carbon monoxide.
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extensive disease, patients 2 and 3 with limited disease);
decreased diffusing capacity (DLCO) with normal lung vol-
umes (patient 1, 47.2%; patient 2, 72.1%; patient 3, 78%);
detectable right ventricular systolic pressure (patient 1,
28 mmHg; patient 2, 22 mmHg); anaemia (patient 1,
haemoglobin 9.5 g/dl; patient 2, haemoglobin 11.8 g/dl),
raised ESR (patient 1, 86 mm/h; patient 2, 46 mm/h),
raised CRP (patient 1, 8.1 mg/dl; patient 2, 1.75 mg/dl).
The immunology profile showed ANAs (patients 1, 2 and
3), anti-topo I antibodies (patients 2 and 3) and anti-PMscl
100 antibodies (patient 3). Patient 3 was also positive for
RF and anti-CCP2 antibodies.
Patient 1 received treatment with iloprost, bosentan,
CYC, AZA, HCQ and steroids. An initial response was
seen, but 2 months after completing CYC and on AZA,
lung involvement worsened, with an increased extent of
ground glass appearance and fibrosis on chest CT. Digital
ulcers reappeared at this point and the patient had a steep
weight loss. Patient 2 was refractory to steroids, bosen-
tan, CYC and AZA. Patient 3, with an overlap of SSc and
RA, was treated with MTX, HCQ, steroids and etanercept,
which was switched to adalimumab after an injection site
reaction. She had poor control of arthritis and progression
of lung involvement. The decision was to administer TCZ
in all three of the patients.
Overall, TCZ was well tolerated, and all the patients
experienced a general improvement in coping with
normal daily activities. Clinical and laboratorial parameters
and pulmonary function tests were reassessed 6 months
after the first administration, and chest CT was repeated
after 9 months (Table 1). The patient global assessment
improved by 30 (70 to 40), 40 (70 to 30) and 50 (60 to 10) in
patients 1, 2 and 3, respectively. Skin thickness evaluated
with the 17 site modified Rodnan skin score improved in
patient 1 (from 17 to 10) and patient 2 (from 41 to 25).
Patient 3 varied from 7 to 5. Simultaneously, the two
patients with digital ulcers showed complete healing. An
increase in haemoglobin levels and body weight was also
noted, which was accompanied by a decrease in ESR and
CRP levels and thus reflected the anti-inflammatory
effects of TCZ. There was a halt in the progression of
lung disease in patient 1 (no progression on CT; DLCO
50%) and patient 2 (no progression on CT; DLCO 75%)
and only a slight CT worsening and decrease in DLCO to
65% in patient 3. All the patients had an important and
long-standing lung involvement with fibrosis, and there-
fore the potential benefits of TCZ (or lack of) should be
considered with caution. Patient 3 had RA/SSc overlap
syndrome, with previous treatment with MTX and active
synovitis that ameliorated after treatment with TCZ
(DAS28 decreased from 3.82 to 2.87 in 6 months), which
is consistent with previous evidence. Our mini-series
suggests that TCZ might be a valuable treatment for
SSc. These results reinforce the need for clinical trials
using TCZ in diffuse SSc.
Rheumatology key message
. TCZ could be a valuable option for the treatment of
SSc.
Funding: No specific funding was received from any
funding bodies in the public, commercial or not-for-profit
sectors to carry out the work described in this manuscript.
Disclosure statement: The authors have declared no
conflicts of interest.
Marisa Fernandes das Neves1,2, Susana Oliveira1,
Marta C. Amaral1,2 and Jose´ Delgado Alves1,2
1Immunomediated Systemic Diseases Unit, Medicine 4,
Fernando Fonseca Hospital, Amadora and 2Center for
Chronic Diseases (CEDOC), Faculty of Medical Sciences, New
University of Lisbon, Lisbon, Portugal
Accepted 16 September 2014
Correspondence to: Jose´ Delgado Alves, Department of
Medicine IV, Fernando Fonseca Hospital, Estrada do IC19,
2720-276 Amadora, Portugal.
E-mail: jose.alves@fcm.unl.pt
References
1 Leask A. Emerging targets for the treatment of
scleroderma. Expert Opin Emerg Drugs 2012;17:1739.
2 Denton CP, Ong VH. Targeted therapies for systemic
sclerosis. Nat Rev Rheumatol 2013;9:45164.
3 Barnes TC, Anderson ME, Moots RJ. The many faces of
interleukin-6: the role of IL-6 in inflammation,
vasculopathy, and fibrosis in systemic sclerosis. Inter J
Rheumatol 2011;2011:721608.
4 Khan K, Xu S, Nihtyanova S et al. Clinical and
pathological significance of interleukin 6 overexpression in
systemic sclerosis. Ann Rheum Dis 2012;71:123542.
5 O’Reilly S, Cant R, Ciechomska M, van Laar JM.
Interleukin-6: a new therapeutic target in systemic
sclerosis? Clin Transl Immunol 2013;2:e4.
6 Shima Y, Kuwahara Y, Murota H et al. The skin of patients
with systemic sclerosis softened during the treatment with
anti-IL-6 receptor antibody tocilizumab. Rheumatology
2010;49:240812.
7 Elhai M, Meunier M, Matucci-Cerinic M et al.
Outcomes of patients with systemic
sclerosis-associated polyarthritis and myopathy
treated with tocilizumab or abatacept: a EUSTAR
observational study. Ann Rheum Dis 2013;72:121720.
8 Goh NS, Desai SR, Veeraraghavan S et al. Interstitial
lung disease in systemic sclerosis: a simple staging
system. Am J Respir Crit Care Med 2008;177:124854.
Rheumatology 2015;54:372373
doi:10.1093/rheumatology/keu353
Advance Access publication 8 September 2014
Comment on: Induction treatment of
ANCA-associated vasculitis with a single
dose of rituximab
SIR, In their report of 19 ANCA vasculitis patients, Turner-
Stokes and colleagues [1] present interesting data on
remission induction treatment with a single dose of
rituximab. The authors conclude that the efficacy of the
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